Capricor Therapeutics(US:CAPR) GlobeNewswire News Room·2025-08-04 20:34Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead cell therapy candidate, deramiocel, which was intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [3][4]. Group 1: Allegations and Impact - The lawsuit claims that Capricor provided investors with overly positive information about deramiocel's potential to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts related to its Phase 2 HOPE-2 trial data [3][4]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness and the need for additional clinical data, Capricor's stock price dropped from $11.40 to $7.64 per share [3][4]. Group 2: Class Action Details - The class period for the lawsuit is defined as October 9, 2024, to July 10, 2025, and shareholders are encouraged to register for participation by September 15, 2025 [3][4]. - Shareholders who register will receive updates on the case's progress and can seek lead plaintiff status without any cost or obligation [4]. Group 3: Law Firm Information - The Gross Law Firm, which is handling the case, is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].